Prosonix is a specialty pharmaceutical company developing a portfolio of inhaled respiratory medicines of known and approved drugs, using its own particle engineering technology. Prosonix' drug development is based on a novel ultrasonic particle engineering approach. Its proprietary technology enables Prosonix to develop ‘smart’ excipient-free, drug-only inhalable particles that are specifically designed to optimally target the site of action in the lung, precisely and consistently, delivering maximum clinical effect. Prosonix’ lead products include a generic drug for asthma (PSX1001) and for chronic obstructive pulmonary disease (PSX1002). The company is also advancing the development of its next-generation combination respiratory medicines. In addition to its internal respiratory pipeline, Prosonix worked on numerous co-development partnerships with leading pharmaceutical companies.
15 May 2015, Gimv announced that portfolio company Prosonix (Oxford, UK) is to be acquired by Circassia Pharmaceuticals PLC (www.circassia.co.uk), a clinical-stage specialty biopharmaceutical company listed on London Stock Exchange (Ticker: CIR.L).
- Activity: Pharma company developing novel respiratory medicines
- Website: www.prosonix.co.uk
- Location: United Kingdom
- Entry: 2012
- Platform: Health & Care